Liver and Bile
J Hepatol. 2022;76(4):862–73
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab versus sorafenib for unresectable hepatocellular carcinoma
Background and aims: IMbrave150 demonstrated that atezolizumab plus bevacizumab led to significantly improved overall survival (OS) and progression-free survival (PFS) compared with sorafenib in patients with unresectable hepatocellular carcinoma at the primary analysis (after a median 8.6 months of follow-up). Updated data were presented after 12 months of additional follow-up.
Methods: Patients with systemic treatment-naive, unresectable hepatocellular carcinoma were randomized 2:1 to receive 1200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks or 400 mg sorafenib orally twice daily in this open-label, phase 3 study. Co-primary end points were OS and PFS by independently assessed RECIST 1.1 in the intention-to-treat population. Secondary efficacy end points included objective response rates and exploratory subgroup efficacy analyses. This is a post-hoc updated analysis of efficacy and safety.
Results: From March 15, 2018, to January 30, 2019, 501 patients (intention-to-treat population) were randomly allocated to receive atezolizumab plus bevacizumab (n = 336) or sorafenib (n = 165). On August 31, 2020, after a median 15.6 (range, 0–28.6) months of follow-up, the median OS was 19.2 months (95% confidence interval [CI]: 17.0–23.7) with atezolizumab plus bevacizumab and 13.4 months (95% CI: 11.4–16.9) with sorafenib (hazard ratio [HR] = 0.66; 95% CI: 0.52–0.85; descriptive p < 0.001). The median PFS was 6.9 (95% CI: 5.7–8.6) and 4.3 (95% CI: 4.0–5.6) months in the respective treatment groups (HR = 0.65; 95% CI: 0.53–0.81; descriptive p < 0.001). Treatment-related grade 3/4 adverse events occurred in 143 (43%) of 329 and 72 (46%) of 156 safety-evaluable patients in the respective groups, and treatment-related grade 5 events occurred in 6 (2%) and 1 (< 1%) patients.
Conclusion: After longer follow-up, atezolizumab plus bevacizumab maintained clinically meaningful survival benefits over sorafenib and had a safety profile consistent with the primary analysis.